Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Advancing HES Care with AstraZeneca’s FASENRA: Insights from James Teague & Princess U. Ogbogu

Shots:  Could a targeted biologic therapy help address the longstanding unmet needs in hypereosinophilic syndrome (HES)? AstraZeneca’s FASENRA has now received US approval for HES, introducing a once-monthly treatment option for patients living with this rare and often underdiagnosed eosinophilic disorder  Results from the Phase III NATRON trial showed that FASENRA reduced the risk of first HES flare by 65% vs placebo,…
June 1, 2026

Read more

VIEWPOINTS_Donna Carstens_2024
VIEWPOINTS

SEA Management: Donna Carstens from AstraZeneca in a Riveting Conversation with PharmaShots

Shots:  Recently AstraZeneca’s FASENRA (benralizumab) received approval from the US FDA as an add-on maintenance treatment for patients (≥ 6 yrs.) with severe asthma and with an eosinophilic phenotype  Today, at PharmaShots we have with us Donna Carstens, Senior Medical Director Respiratory, Fasenra at AstraZeneca  Donna shares insights from the TATE study an open-label, multinational,…
June 3, 2024

Read more

VIEWPOINTS_David Jackson_2024
VIEWPOINTS

SEA Management with Fasenra: David Jackson & Fasenra Team (AZ) Share Insights from the SHAMAL P-IV Study

Shots:  David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV study  SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patients  SHAMAL showcased that ICS…
March 20, 2024

Read more